Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Assets Average (2016 - 2025)

Viking Therapeutics' Assets Average history spans 11 years, with the latest figure at $727.6 million for Q4 2025.

  • For Q4 2025, Assets Average fell 21.18% year-over-year to $727.6 million; the TTM value through Dec 2025 reached $727.6 million, down 21.18%, while the annual FY2025 figure was $812.0 million, 27.2% up from the prior year.
  • Assets Average for Q4 2025 was $727.6 million at Viking Therapeutics, down from $783.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $957.2 million in Q2 2024 and bottomed at $159.7 million in Q1 2023.
  • The 5-year median for Assets Average is $325.7 million (2023), against an average of $480.9 million.
  • The largest annual shift saw Assets Average decreased 24.69% in 2022 before it soared 318.26% in 2024.
  • A 5-year view of Assets Average shows it stood at $217.6 million in 2021, then dropped by 22.96% to $167.6 million in 2022, then surged by 124.08% to $375.6 million in 2023, then soared by 145.78% to $923.1 million in 2024, then dropped by 21.18% to $727.6 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Assets Average are $727.6 million (Q4 2025), $783.6 million (Q3 2025), and $847.4 million (Q2 2025).